Aaron Mansfield, M.D.
Dr. Mansfield is a medical oncologist at Mayo Clinic with a focus on thoracic malignancies and early therapeutics. He is co-director of the Precision Cancer Therapeutics group within the Center for Individualized Medicine. He has played a significant role in clinical trials leading to FDA approval of agents for thoracic malignancies including atezolizumab for small cell lung cancer, pralsetinib for RET-fusion non-small cell lung cancer and the combination of ipilimumab with nivolumab for mesothelioma. His laboratory runs many translational projects to discover and validate biomarkers in thoracic malignancies.
Financial relationships
-
Attribution:SelfType of financial relationship:TravelIneligible company:RocheDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbVieTopic:Advisory BoardDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaTopic:Advisory BoardDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:Advisory BoardDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenentechTopic:Advisory BoardDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:Steering CommitteeDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Johnson & Johnson Global ServicesTopic:Steering CommitteeDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Chugai Pharmaceutical Co Ltd (Roche)Topic:Speaking EngagementDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Rising TideTopic:Grant ReviewerDate added:07/26/2022Date updated:07/26/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:TRIPTYCH Health PartnersTopic:Expert Think TankDate added:07/26/2022Date updated:07/26/2022